Elfrida R. Benjamin

Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

Dominique P. Germain, Derralynn Hughes, Daniel G. Bichet et al. · New England Journal of Medicine · 2016 · 556 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

Derralynn Hughes, Suma P. Shankar, Gere Sunder–Plassmann et al. · Journal of Medical Genetics · 2016 · 386 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat

Elfrida R. Benjamin, Maria Cecilia Della Valle, Xiaoyang Wu et al. · Genetics in Medicine · 2016 · 209 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of <b>β</b>‐glucosidase

Richie Khanna, Elfrida R. Benjamin, Lee Pellegrino et al. · FEBS Journal · 2010 · 158 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16

The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease

Richie Khanna, Rebecca Soska, Yi Lun et al. · Molecular Therapy · 2009 · 140 citations · Full text

Life Sciences, Biochemistry, Pharmacology +16